Relaxin-3 is known to play a role in appetite regulation, increasing food intake and body weight. This study aimed to assess the relation of relaxin-3 with ERS1 XbaI and PvuII polymorphisms. One hundred female patients with metabolic syndrome were investigated. The genotypes of ESR1 XbaI and PvuII polymorphisms were assessed with PCR-RFLP. Serum relaxin-3 level was measured for all participants using ELISA.
Introduction
Relaxin-3 (also known as INSL7) is an insulin/relaxin superfamily neuropeptide that was first discovered in 2002 (Bathgate et al. 2002) . It is involved in the regulation of food intake, stress response, and arousal and exploratory behaviors (Hu et al., 2016) .
Metabolic syndrome is a combination of several physiological, biochemical, clinical, and metabolic factors that increase the risk of cardiovascular disease, type 2 diabetes mellitus. Insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood pressure, prothrombotic state, and chronic stress are the several factors that constitute the syndrome (Kaur, 2014) . The prevalence of metabolic syndrome in women appears to be increasing, especially in those of childbearing age (Ramos and Olden, 2008) .
Levels of estrogen or its receptors were linked to metabolic syndrome in both humans and experimental animals (Matic et al., 2013 
Materials and methods

Study population
The study was conducted on 100 female metabolic syndrome patients. They were selected from the 
Relaxin-3 measurement
Peripheral blood was drawn after a 12 h fast and a portion was collected with EDTA and used for DNA extraction. The serum was separated from the remaining portion of the blood samples and used for measurement of relaxin-3 level using EIAab human relaxin-3 ELISA kit (Wuhan EIAab Science Co., Ltd., China).
Genomic DNA extraction and genotyping
Genomic DNA was isolated from 300 μL of whole Figure 2) . The cleavage products were electrophoresed on a 1% agarose gel.
Statistical analysis
Hardy-Weinberg's equilibrium was evaluated using 
Results and discussion
ERα has been found to play a role in glucose and lipid homeostasis in several tissues including the brain, skeletal muscle, adipose tissue, pancreas, liver, and heart; that may have important implications to risk factors associated with the metabolic syndrome (Barros and Gustafsson, 2011) .
The genotype distribution of ESR1 XbaI and PvuII polymorphisms in the study sample is presented in Hardy-Weinberg's equilibrium. These results match with previous findings; where the minor G allele of XbaI polymorphism of the ESR1 gene, was found to be associated with metabolic syndrome, whereas PvuII polymorphism showed no association with metabolic syndrome (Ghattas et al., 2013a) . Relaxin-3 was considered to be a potential marker of metabolic syndrome where serum levels of relaxin-3 were higher among metabolic syndrome female patients compared to normal subjects (Ghattas et al., 2013b ).
As shown in
This study assumes a possible role of estrogen in regulation of relaxin-3 secretion. This assumption can be supported by the suggested role of relxin-3 in regulation of the hypothalamic-pituitary-gonadal axis (McGowan et al., 2008) . The interaction between the hypothalamic-pituitary-gonadal axis and estrogen is well known (Chrousos et al., 1998) . Relaxin is concerned with follicle growth, ovulation, implantation and placental establishment (Anand-Ivell and Ivell, 2014). Additionally, relaxin-3 was found to be associated with lipid accumulation in adipocytes (Yamamoto et al., 2014) .
Conclusion
The GG genotype of ESR1 XbaI polymorphism was significantly associated with increased serum relaxin-3 levels in women with metabolic syndrome. In contrast, ESR1 PvuII polymorphism genotypes showed no association with serum relaxin-3 levels. 
